# Myomo, Inc.: financial statements, quarterly

MYO · NYSE · CIK 1369290 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/myo.md) · [Financials](/companies/myo/financials.md) · [Filings](/companies/myo/filings.md) · [Insiders](/companies/myo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/myo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5.1](/filings/0000950170-24-122331.md) | [4.8 d](/filings/0000950170-25-036349.md) | [3.8](/filings/0000950170-25-065682.md) | [7.5](/filings/0000950170-25-106564.md) | [9.2](/filings/0001193125-25-274278.md) | [12.1 d](/filings/0001193125-26-098531.md) | [9.8](/filings/0001193125-26-211988.md) | [9.7](/filings/0001193125-26-335149.md) | [10.1](/filings/0001193125-25-274278.md) | [11.4 d](/filings/0001193125-26-098531.md) | [10.1](/filings/0001193125-26-211988.md) | [11.7](/filings/0001193125-26-335149.md) |
| Cost of revenue | $m | [1.6](/filings/0000950170-24-122331.md) | [1.7 d](/filings/0000950170-25-036349.md) | [1.5](/filings/0000950170-25-065682.md) | [2.2](/filings/0000950170-25-106564.md) | [2.3](/filings/0001193125-25-274278.md) | [3.5 d](/filings/0001193125-26-098531.md) | [3.2](/filings/0001193125-26-211988.md) | [3.6](/filings/0001193125-26-335149.md) | [3.6](/filings/0001193125-25-274278.md) | [3.6 d](/filings/0001193125-26-098531.md) | [3.2](/filings/0001193125-26-211988.md) | [3.3](/filings/0001193125-26-335149.md) |
| Gross profit | $m | [3.5](/filings/0000950170-24-122331.md) | [3.1 d](/filings/0000950170-25-036349.md) | [2.3](/filings/0000950170-25-065682.md) | [5.3](/filings/0000950170-25-106564.md) | [6.9](/filings/0001193125-25-274278.md) | [8.6 d](/filings/0001193125-26-098531.md) | [6.6](/filings/0001193125-26-211988.md) | [6.1](/filings/0001193125-26-335149.md) | [6.4](/filings/0001193125-25-274278.md) | [7.8 d](/filings/0001193125-26-098531.md) | [6.9](/filings/0001193125-26-211988.md) | [8.4](/filings/0001193125-26-335149.md) |
| Research and development | $m | [0.7](/filings/0000950170-24-122331.md) | [0.9 d](/filings/0000950170-25-036349.md) | [1.0](/filings/0000950170-25-065682.md) | [1.0](/filings/0000950170-25-106564.md) | [1.2](/filings/0001193125-25-274278.md) | [1.6 d](/filings/0001193125-26-098531.md) | [1.8](/filings/0001193125-26-211988.md) | [2.0](/filings/0001193125-26-335149.md) | [1.5](/filings/0001193125-25-274278.md) | [1.6 d](/filings/0001193125-26-098531.md) | [1.6](/filings/0001193125-26-211988.md) | [1.7](/filings/0001193125-26-335149.md) |
| Selling, general and administrative | $m | [4.8](/filings/0000950170-23-060417.md) | [4.7 d](/filings/0000950170-24-028326.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(2.0)](/filings/0000950170-24-122331.md) | [(2.4) d](/filings/0000950170-25-036349.md) | [(3.9)](/filings/0000950170-25-065682.md) | [(1.1)](/filings/0000950170-25-106564.md) | [(1.0)](/filings/0001193125-25-274278.md) | [(0.2) d](/filings/0001193125-26-098531.md) | [(3.5)](/filings/0001193125-26-211988.md) | [(4.6)](/filings/0001193125-26-335149.md) | [(3.5)](/filings/0001193125-25-274278.md) | [(2.8) d](/filings/0001193125-26-098531.md) | [(3.2)](/filings/0001193125-26-211988.md) | [(2.3)](/filings/0001193125-26-335149.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-122331.md) | [0.1 d](/filings/0000950170-25-036349.md) | [0.1](/filings/0000950170-25-065682.md) | [0.1](/filings/0000950170-25-106564.md) | [0.1](/filings/0001193125-25-274278.md) | [0.1 d](/filings/0001193125-26-098531.md) | [0.1](/filings/0001193125-26-211988.md) | [0.1](/filings/0001193125-26-335149.md) | [0.1](/filings/0001193125-25-274278.md) | [0.1 d](/filings/0001193125-26-098531.md) | [0.2](/filings/0001193125-26-211988.md) | [0.0](/filings/0001193125-26-335149.md) |
| Net income | $m | [(2.0)](/filings/0000950170-24-122331.md) | [(2.5) d](/filings/0000950170-25-036349.md) | [(3.8)](/filings/0001193125-25-274278.md) | [(1.1)](/filings/0001193125-25-274278.md) | [(1.0)](/filings/0001193125-25-274278.md) | [(0.3) d](/filings/0001193125-26-098531.md) | [(3.5)](/filings/0001193125-26-335149.md) | [(4.6)](/filings/0001193125-26-335149.md) | [(3.7)](/filings/0001193125-25-274278.md) | [(3.8) d](/filings/0001193125-26-098531.md) | [(3.0)](/filings/0001193125-26-335149.md) | [(4.0)](/filings/0001193125-26-335149.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0000950170-24-122331.md) | not reported | [(0.10)](/filings/0000950170-25-065682.md) | [(0.03)](/filings/0000950170-25-106564.md) | [(0.03)](/filings/0001193125-25-274278.md) | not reported | [(0.08)](/filings/0001193125-26-211988.md) | [(0.11)](/filings/0001193125-26-335149.md) | [(0.09)](/filings/0001193125-25-274278.md) | not reported | [(0.07)](/filings/0001193125-26-211988.md) | [(0.09)](/filings/0001193125-26-335149.md) |
| Basic EPS | $ per share | [(0.06)](/filings/0000950170-24-122331.md) | not reported | [(0.10)](/filings/0000950170-25-065682.md) | [(0.03)](/filings/0000950170-25-106564.md) | [(0.03)](/filings/0001193125-25-274278.md) | not reported | [(0.08)](/filings/0001193125-26-211988.md) | [(0.11)](/filings/0001193125-26-335149.md) | [(0.09)](/filings/0001193125-25-274278.md) | not reported | [(0.07)](/filings/0001193125-26-211988.md) | [(0.09)](/filings/0001193125-26-335149.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.9](/filings/0000950170-23-060417.md) | [6.9](/filings/0000950170-25-036349.md) | [5.4](/filings/0000950170-24-055660.md) | [5.8](/filings/0000950170-24-091839.md) | [6.6](/filings/0000950170-24-122331.md) | [24.4](/filings/0001193125-26-098531.md) | [19.8](/filings/0000950170-25-065682.md) | [14.2](/filings/0000950170-25-106564.md) | [12.6](/filings/0001193125-25-274278.md) | [14.1](/filings/0001193125-26-335149.md) | [11.4](/filings/0001193125-26-211988.md) | [11.2](/filings/0001193125-26-335149.md) |
| Current assets | $m | [16.0](/filings/0000950170-23-060417.md) | [13.7](/filings/0000950170-25-036349.md) | [15.7](/filings/0000950170-24-055660.md) | [15.1](/filings/0000950170-24-091839.md) | [14.7](/filings/0000950170-24-122331.md) | [32.8](/filings/0001193125-26-098531.md) | [31.1](/filings/0000950170-25-065682.md) | [28.0](/filings/0000950170-25-106564.md) | [22.9](/filings/0001193125-25-274278.md) | [27.6](/filings/0001193125-26-335149.md) | [25.7](/filings/0001193125-26-211988.md) | [24.5](/filings/0001193125-26-335149.md) |
| Total assets | $m | [17.1](/filings/0000950170-23-060417.md) | [14.6](/filings/0000950170-25-036349.md) | [16.5](/filings/0000950170-24-055660.md) | [16.2](/filings/0000950170-24-091839.md) | [16.3](/filings/0000950170-24-122331.md) | [42.2](/filings/0001193125-26-098531.md) | [40.9](/filings/0000950170-25-065682.md) | [38.7](/filings/0000950170-25-106564.md) | [34.1](/filings/0001193125-25-274278.md) | [38.6](/filings/0001193125-26-335149.md) | [36.8](/filings/0001193125-26-211988.md) | [35.3](/filings/0001193125-26-335149.md) |
| Current liabilities | $m | [5.8](/filings/0000950170-23-060417.md) | [5.5](/filings/0000950170-25-036349.md) | [5.6](/filings/0000950170-24-055660.md) | [6.5](/filings/0000950170-24-091839.md) | [7.0](/filings/0000950170-24-122331.md) | [10.2](/filings/0001193125-26-098531.md) | [11.7](/filings/0000950170-25-065682.md) | [11.8](/filings/0000950170-25-106564.md) | [9.2](/filings/0001193125-25-274278.md) | [8.3](/filings/0001193125-26-335149.md) | [9.4](/filings/0001193125-26-211988.md) | [10.6](/filings/0001193125-26-335149.md) |
| Total liabilities | $m | [6.0](/filings/0000950170-23-060417.md) | [5.6](/filings/0000950170-25-036349.md) | [5.6](/filings/0000950170-24-055660.md) | [6.5](/filings/0000950170-24-091839.md) | [7.0](/filings/0000950170-24-122331.md) | [17.5](/filings/0001193125-26-098531.md) | [19.2](/filings/0000950170-25-065682.md) | [21.1](/filings/0000950170-25-106564.md) | [19.5](/filings/0001193125-25-274278.md) | [27.2](/filings/0001193125-26-335149.md) | [27.8](/filings/0001193125-26-211988.md) | [29.5](/filings/0001193125-26-335149.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [11.2](/filings/0001193125-26-211988.md) | not reported | [1.3](/filings/0000950170-25-106564.md) | [2.4](/filings/0001193125-25-274278.md) | [11.2](/filings/0001193125-26-335149.md) | [10.9](/filings/0001193125-26-211988.md) | [11.5](/filings/0001193125-26-335149.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [3.0](/filings/0001193125-26-098531.md) | not reported | [0.2](/filings/0000950170-25-106564.md) | [0.6](/filings/0001193125-25-274278.md) | [0.0](/filings/0001193125-26-335149.md) | [2.7](/filings/0001193125-26-211988.md) | [0.4](/filings/0001193125-26-335149.md) |
| Shareholders' equity | $m | [11.0](/filings/0000950170-24-122331.md) | [9.0](/filings/0001193125-26-098531.md) | [10.9](/filings/0001193125-25-274278.md) | [9.7](/filings/0001193125-25-274278.md) | [9.3](/filings/0001193125-25-274278.md) | [24.7](/filings/0001193125-26-335149.md) | [21.7](/filings/0001193125-26-335149.md) | [17.6](/filings/0001193125-26-335149.md) | [14.6](/filings/0001193125-25-274278.md) | [11.4](/filings/0001193125-26-335149.md) | [9.0](/filings/0001193125-26-335149.md) | [5.8](/filings/0001193125-26-335149.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,715) d](/filings/0000950170-24-122331.md) | [(2,356) d](/filings/0000950170-25-036349.md) | [(3,246)](/filings/0000950170-25-065682.md) | [(1,916) d](/filings/0000950170-25-106564.md) | [(1,494) d](/filings/0001193125-25-274278.md) | [3,366 d](/filings/0001193125-26-098531.md) | [(2,677)](/filings/0001193125-26-211988.md) | [(8,865) d](/filings/0001193125-26-335149.md) | [(1,829) d](/filings/0001193125-25-274278.md) | [(1,140) d](/filings/0001193125-26-098531.md) | [(2,197)](/filings/0001193125-26-211988.md) | [(1,944) d](/filings/0001193125-26-335149.md) |
| Capital expenditure | $k | [54.1 d](/filings/0000950170-24-122331.md) | [31.7 d](/filings/0000950170-25-036349.md) | [59.8](/filings/0000950170-25-065682.md) | [119 d](/filings/0000950170-25-106564.md) | [321 d](/filings/0001193125-25-274278.md) | [860 d](/filings/0001193125-26-098531.md) | [671](/filings/0001193125-26-211988.md) | [221 d](/filings/0001193125-26-335149.md) | [2,089 d](/filings/0001193125-25-274278.md) | [(1,239) d](/filings/0001193125-26-098531.md) | [328](/filings/0001193125-26-211988.md) | [32.4 d](/filings/0001193125-26-335149.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.1](/filings/0000950170-23-060417.md) | [24.2](/filings/0000950170-24-055660.md) | [28.0](/filings/0000950170-24-091839.md) | [35.3](/filings/0000950170-24-122331.md) | [36.8](/filings/0000950170-25-065682.md) | [37.4](/filings/0000950170-25-106564.md) | [38.0](/filings/0001193125-25-274278.md) | [41.5](/filings/0001193125-26-211988.md) | [41.6](/filings/0001193125-26-335149.md) | [42.2](/filings/0001193125-25-274278.md) | [42.3](/filings/0001193125-26-211988.md) | [42.7](/filings/0001193125-26-335149.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 39,607,854 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335149.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.